These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 26626621)
1. Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review. Leaver K; Poston KL Neuropsychol Rev; 2015 Dec; 25(4):411-23. PubMed ID: 26626621 [TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study. Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029 [TBL] [Abstract][Full Text] [Related]
3. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614 [TBL] [Abstract][Full Text] [Related]
4. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease. Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633 [TBL] [Abstract][Full Text] [Related]
5. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. Kang JH; Mollenhauer B; Coffey CS; Toledo JB; Weintraub D; Galasko DR; Irwin DJ; Van Deerlin V; Chen-Plotkin AS; Caspell-Garcia C; Waligórska T; Taylor P; Shah N; Pan S; Zero P; Frasier M; Marek K; Kieburtz K; Jennings D; Tanner CM; Simuni T; Singleton A; Toga AW; Chowdhury S; Trojanowski JQ; Shaw LM; Acta Neuropathol; 2016 Jun; 131(6):935-49. PubMed ID: 27021906 [TBL] [Abstract][Full Text] [Related]
6. CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease. Oosterveld LP; Kuiper TI; Majbour NK; Verberk IMW; van Dijk KD; Twisk JWR; El-Agnaf OM; Teunissen CE; Weinstein HC; Klein M; Berendse HW; van de Berg WDJ Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198266 [TBL] [Abstract][Full Text] [Related]
7. CSF biomarkers and clinical progression of Parkinson disease. Hall S; Surova Y; Öhrfelt A; Zetterberg H; Lindqvist D; Hansson O Neurology; 2015 Jan; 84(1):57-63. PubMed ID: 25411441 [TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease. Johar I; Mollenhauer B; Aarsland D Int Rev Neurobiol; 2017; 132():275-294. PubMed ID: 28554411 [TBL] [Abstract][Full Text] [Related]
9. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease. Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300 [TBL] [Abstract][Full Text] [Related]
10. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. Schrag A; Siddiqui UF; Anastasiou Z; Weintraub D; Schott JM Lancet Neurol; 2017 Jan; 16(1):66-75. PubMed ID: 27866858 [TBL] [Abstract][Full Text] [Related]
11. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984 [TBL] [Abstract][Full Text] [Related]
12. Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study. Yu SY; Zuo LJ; Wang F; Chen ZJ; Hu Y; Wang YJ; Wang XM; Zhang W BMC Neurol; 2014 May; 14():113. PubMed ID: 24884485 [TBL] [Abstract][Full Text] [Related]
16. CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease. Liu C; Cholerton B; Shi M; Ginghina C; Cain KC; Auinger P; ; Zhang J Parkinsonism Relat Disord; 2015 Mar; 21(3):271-6. PubMed ID: 25596881 [TBL] [Abstract][Full Text] [Related]
17. Changes of cerebrospinal fluid Aβ Hu X; Yang Y; Gong D Neurol Sci; 2017 Nov; 38(11):1953-1961. PubMed ID: 28808876 [TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings. Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322 [TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. Bäckström DC; Eriksson Domellöf M; Linder J; Olsson B; Öhrfelt A; Trupp M; Zetterberg H; Blennow K; Forsgren L JAMA Neurol; 2015 Oct; 72(10):1175-82. PubMed ID: 26258692 [TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients. Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]